Insider Trading Alert - SLAB, ADK And ADVS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 10, 2014, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.29 to $203,469,000.00.

Highlighted Stocks Traded by Insiders:

Silicon Laboratories (SLAB) - FREE Research Report

Ivester Jonathan D, who is Sr VP, Strategic Operations at Silicon Laboratories, sold 3,000 shares at $46.79 on Dec. 10, 2014. Following this transaction, the Sr VP, Strategic Operations owned 85,684 shares meaning that the stake was reduced by 3.38% with the 3,000-share transaction.

The shares most recently traded at $46.90, up $0.11, or 0.23% since the insider transaction. Historical insider transactions for Silicon Laboratories go as follows:

  • 4-Week # shares bought: 1,400
  • 4-Week # shares sold: 3,000
  • 12-Week # shares bought: 1,400
  • 12-Week # shares sold: 21,287
  • 24-Week # shares bought: 1,400
  • 24-Week # shares sold: 33,703

The average volume for Silicon Laboratories has been 366,400 shares per day over the past 30 days. Silicon Laboratories has a market cap of $2.0 billion and is part of the technology sector and electronics industry. Shares are up 5.43% year-to-date as of the close of trading on Wednesday.

Silicon Laboratories Inc., a fabless semiconductor company, designs and develops analog-intensive, mixed-signal integrated circuits (ICs). The company has a P/E ratio of 53.4. Currently, there are 7 analysts who rate Silicon Laboratories a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SLAB - FREE

TheStreet Quant Ratings rates Silicon Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Silicon Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AdCare Health Systems (ADK) - FREE Research Report

Mcbride William Iii, who is Ceo & President at AdCare Health Systems, bought 6,000 shares at $3.80 on Dec. 10, 2014. Following this transaction, the Ceo & President owned 156,000 shares meaning that the stake was boosted by 4% with the 6,000-share transaction.

The shares most recently traded at $3.70, down $0.10, or 2.65% since the insider transaction. Historical insider transactions for AdCare Health Systems go as follows:

  • 4-Week # shares sold: 44,425
  • 12-Week # shares sold: 153,892
  • 24-Week # shares sold: 153,892

The average volume for AdCare Health Systems has been 46,100 shares per day over the past 30 days. AdCare Health Systems has a market cap of $71.4 million and is part of the health care sector and health services industry. Shares are down 12.09% year-to-date as of the close of trading on Wednesday.

AdCare Health Systems, Inc., through its subsidiaries, owns and manages skilled nursing facilities and assisted living facilities in Alabama, Arkansas, Georgia, Missouri, North Carolina, Ohio, Oklahoma, and South Carolina. Currently, there are 2 analysts who rate AdCare Health Systems a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ADK - FREE

TheStreet Quant Ratings rates AdCare Health Systems as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full AdCare Health Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Advent Software (ADVS) - FREE Research Report

Sperling Anthony, who is EVP, Global Client Experience at Advent Software, sold 12,084 shares at $30.72 on Dec. 10, 2014. Following this transaction, the EVP, Global Client Experience owned 57,652 shares meaning that the stake was reduced by 17.33% with the 12,084-share transaction.

The shares most recently traded at $31.40, up $0.68, or 2.17% since the insider transaction. Historical insider transactions for Advent Software go as follows:

  • 4-Week # shares sold: 7,766
  • 12-Week # shares sold: 13,266
  • 24-Week # shares sold: 15,984

The average volume for Advent Software has been 398,600 shares per day over the past 30 days. Advent Software has a market cap of $1.6 billion and is part of the technology sector and computer software & services industry. Shares are down 10.82% year-to-date as of the close of trading on Wednesday.

Advent Software, Inc. provides software products and services for automating and integrating data and work flows across the investment management organization, as well as between the investment management organization and external parties worldwide. The stock currently has a dividend yield of 1.64%. The company has a P/E ratio of 36.4. Currently, there are 2 analysts who rate Advent Software a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ADVS - FREE

TheStreet Quant Ratings rates Advent Software as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and good cash flow from operations. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Advent Software Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists